Rules database changelog

Cast is a compliance aid, not a compliance authority. The Service screens every generated post against a jurisdiction-specific rules database covering privacy law, drug-advertising regulators, nursing licensing bodies (Registered Nurses, Licensed/Registered Practical Nurses, and equivalent classes such as Enrolled Nurses and Nursing Associates), and ad-disclosure rules. This page tracks every change we make to that database and the operational commitments we make to keep it current.

For the full disclaimer of what the Service does and does not do, see Section 8 of the Terms of Service.

Operational commitments

• Biweekly review. We review the rules database at least every two weeks against published guidance from each covered regulator.
• 7-business-day update window.When a covered regulator publishes HIGH-severity guidance — a new rule, an enforcement action that changes interpretation, or a withdrawn standard — we commit to updating the database within seven business days.
• Currency date on every screening result. Each output card shows the rules-database currency date so you can verify what your post was screened against.
• Public changelog entry for every database version.Every bump — even a one-line clarification — gets an entry on this page with the effective date.

This is an operational SLA, not legal advice. The Service does not replace your professional judgment, your licensing body’s published standards, or human editorial review. You are solely responsible for reviewing every post before publishing it.

Jurisdictions and regulators monitored

Cast actively monitors guidance from the following bodies. The licensing-body column covers both Registered Nurses and Licensed/Registered Practical Nurses (or the equivalent class in that jurisdiction, such as Enrolled Nurses or Nursing Associates).

Changelog

v1.2.2 — 2026-08-13 (biweekly review · two regulator updates logged · one calendared screening change for 2026-12-26)

Routine biweekly review completed for the 2026-08-13 cycle. Two covered regulators published HIGH-severity guidance since the previous review; both are logged here within the 7-business-day SLA window.

Update 1 — Medsafe (New Zealand): expanded general labelling exemptions. Published 2026-08-04, effective 2026-08-11. Medsafe extended the classes of medicine products and packaging types eligible for a general (non-time-limited) labelling exemption under Regulation 12(5) of the Medicines Regulations 1984, and issued GRTPNZ: Labelling of Medicines and Related Products (Edition 2.0, August 2026) along with updated New Medicine Application (NMA) and Changed Medicine Notification (CMN) forms. The expansion covers medical gases; small single- and multi-dose containers under 25 mL; multivalent vaccines; personalised prescription medicines; whole blood and blood components (excluding fractionated products); intermediate and transparent packaging; certain fixed-dose combination products; and sample or starter packs. Controlled drugs and related products are explicitly excluded. Source: Medsafe — General Labelling Exemptions.

Scope determination for Update 1: no screening change. This regulation governs medicine manufacturers, sponsors, and market-authorization holders— who must label containers under section 44 of the Medicines Act 1981 and what may be omitted from the container label. Cast’s screening surface — privacy, scope of practice, drug-and-treatment claims, and ad disclosure for nurse-creator social content — is not affected. A New Zealand nurse-creator posting about medicine handling remains subject to Medsafe’s therapeutic-goods advertising rules and the Therapeutic Products Advertising Code, which are already screened under v1.0. The expanded exemption does not permit any claim in creator content that was previously prohibited.

Update 2 — US FDA: COVID-19 device EUAs terminate 2026-12-26. Published 2026-08-11 on the In Vitro Diagnostics EUAs — Antigen Diagnostic Tests for SARS-CoV-2 page and companion pages. On 2026-06-29 the HHS Secretary determined that circumstances no longer justify emergency-use authorization for (1) SARS-CoV-2 in-vitro diagnostics (antigen, molecular, and serology / adaptive-immune-response tests), (2) personal respiratory protective devices, and (3) medical devices used as alternatives during the emergency. On the basis of that determination, the HHS declarations authorizing emergency use of these medical devices for COVID-19 will be terminated, effective 2026-12-26, at which point the COVID-19 EUAs for all currently listed devices are no longer in effect. In parallel, the COVID-19 enforcement-policy guidances within scope of the Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (List 1) are no longer in effect as of the 2026-08-11 update. Source: FDA — In Vitro Diagnostics EUAs, Antigen Diagnostic Tests for SARS-CoV-2.

Scope determination for Update 2: transparency now, calendared screening change effective 2026-12-26. A US nurse-creator posting about a specific COVID-19 rapid antigen, molecular, or serology test can currently truthfully describe it as “FDA-authorized under EUA” if that device is on the current list. That statement becomes false-in-fact on 2026-12-26 for every device currently listed under the SARS-CoV-2 EUA program — the authorization itself will no longer exist. To avoid the screening database silently going stale on that date, Cast is calendaring a v1.3.0 screening ruleeffective 2026-12-26: any US-jurisdiction output that names a specific COVID-19 in-vitro diagnostic device and characterises it as “FDA-authorized,” “EUA-cleared,” “emergency-use authorized,” or equivalent will be flagged for creator review, with suggested phrasing to check current FDA device status before publishing. The v1.3.0 entry will ship in the biweekly review cycle immediately preceding 2026-12-26 (target cycle: 2026-12-24 review). This entry serves as the public forward notice.

What did not change today. All v1.2 LPN / practical-nurse scope screening, v1.0 privacy / drug-claim / scope-of-practice / ad-disclosure screening, and the regulator-citations panel are unchanged. Content generated between now and 2026-12-25 that references COVID-19 devices continues to be screened under v1.2 rules; the currency date on every screening result identifies which rules version applied.

No other covered regulator(US Boards of Nursing, HIPAA, FTC, Health Canada, provincial nursing colleges, NMC, NMBI, MHRA, EMA, AHPRA, TGA, NCNZ, ASA / ACCC / CMA / CAP / ASAI / Competition Bureau / Privacy Commissioners) published HIGH-severity guidance this cycle that intersects Cast’s screening surface.

v1.2.1 — 2026-06-18 (biweekly review · no screening change)

Routine biweekly review completed for the 2026-06-18 cycle. Reviewed: FDA Federal Register final order FR Doc 2026-12165, effective 2026-06-17, classifying radiological machine learning-based quantitative imaging software with predetermined change control plan into Class II (special controls) under 21 CFR Part 892.

Scope determination: no screening change.This order regulates medical-device manufacturers’ premarket pathway for radiology ML/SaMD products. Cast’s screening surface is not affected. Creator-side risks around radiology AI posts (overstated efficacy, undisclosed endorsement, implicit recommendation) are already covered by v1.0 drug/treatment-claim screening and FTC §255 / ASA / equivalent ad-disclosure rules.

No other covered regulator published HIGH-severity guidance during the 2026-06-18 cycle.

v1.2 — 2026-06-14 (substantive LPN scope-of-practice screening)

This is the first substantive screening change since launch. v1.1 named the practical-nurse-class regulators in the table above but screened practical-nurse content identically to Registered Nurse content. v1.2 introduces a nurse-class selectoron the generate form — Registered Nurse (RN), or the practical-nurse class for your jurisdiction (LPN / LVN in the United States, LPN / RPN in Canada, Enrolled Nurse in Australia and New Zealand, Nursing Associate in the United Kingdom) — and screens practical-nurse content against the scope differences from the Registered Nurse in each jurisdiction that recognizes a practical-nurse class. Your selection is remembered as a sticky default, the same way the jurisdiction selector is.

When you select the practical-nurse class, Cast adds screening across five scope dimensions where that class is more restricted than the Registered Nurse:

• Medication administration. The practical-nurse class administers under a prescriber or RN order and cannot make independent medication decisions; controlled-substance handling is restricted (for example, Australian Enrolled Nurses require a second checker for Schedule 8 medicines, and the California LVN scope is a directed scope requiring an order for every medication).
• IV therapy. IV initiation, IV-push, additives, and central-line / PICC management are restricted or require separate certification or training in most covered jurisdictions (for example, California LVN IV therapy requires separate BVNPT certification, and IV is not a core proficiency for UK Nursing Associates).
• Controlled and delegated acts. The practical-nurse class works under direction or delegation and cannot perform acts that require independent clinical judgment.
• Supervision. The practical-nurse class generally requires an accessible Registered Nurse (or Nurse Practitioner / physician) and, in several jurisdictions, may not practise as the only nurse on duty.
• Assessment. Initial and comprehensive nursing assessment and care-plan initiation are Registered Nurse reservations; the practical-nurse class contributes data collection and focused assessment.

Jurisdiction-specific handling.Ireland’s register (NMBI) has no practical-nurse class — all 12 divisions are at Registered Nurse level — so the nurse-class selector defaults to Registered Nurse for Ireland and no practical-nurse differential is applied. The European Union has no EU-level practical-nurse class (recognition covers the general-care Registered Nurse only), so EU practical-nurse screening is a generic advisory until a specific national regulator is identified.

What did not change. All v1.0 privacy, drug-claim, employer-separation, ad-disclosure, and Registered-Nurse scope-of-practice screening is unchanged. Content generated with Registered Nurse selected behaves exactly as it did in v1.0 and v1.1.

Confidence and limits.The highest-confidence rules are drawn from verified primary-regulator sources: NCSBN Model Rules (US national), BVNPT (California LVN), the Texas Board of Nursing, CNO (Ontario RPN), CLPNA / CLHA (Alberta LPN), NMBA (Australian Enrolled Nurse), and NMBI (Ireland). UK Nursing Associate IV rules and the New Zealand 2025 Enrolled Nurse scope are medium-confidence (employer policy may extend scope beyond the published proficiency standard). EU member-state and some Canadian provincial specifics are advisory only. Cast remains a compliance aid, not a compliance authority — you are still responsible for reviewing every post before publishing.

v1.1 — 2026-06-06 (scope clarification)

Clarifies that Cast’s nursing-profession compliance profile covers both Registered Nurses (RN) and Licensed/Registered Practical Nurses (LPN / RPN) where the jurisdiction recognizes a practical-nurse class, plus the equivalent classes elsewhere (Enrolled Nurses in Australia and New Zealand, Nursing Associates in the United Kingdom). The underlying screening behaviour for v1.1 is identical to v1.0 — this entry is a transparency update to name the LPN-class regulators explicitly in the jurisdictions table.

• Canadian LPN regulators named explicitly: CLHA (Alberta), BCCNM (British Columbia, single college for RN and LPN), CLPNM (Manitoba), CLPNS (Saskatchewan), CNO (Ontario, regulating RN, NP, and RPN), and Atlantic provincial LPN colleges, federated by the Canadian Council for Practical Nurse Regulators (CCPNR).
• US: noted that State Boards of Nursing typically regulate RN, LPN, and LVN under one board; California’s LVN class is regulated by BVNPT separately.
• UK: NMC scope clarified to include Nursing Associates.
• Australia and New Zealand: Enrolled Nurses (NMBA and NCNZ respectively) named explicitly as the LPN-equivalent class.

What was scheduled next (now shipped in v1.2). The substantive review that encodes practical-nurse scope-of-practice differences from RNs (medication-administration limits, IV-therapy authority, controlled-acts, supervision, and assessment) shipped on 2026-06-14 as v1.2 above, under the biweekly review SLA.

v1.0 — 2026-06-04 (launch)

Initial public rules database. Covers seven jurisdictions (US, Canada, UK, Ireland, EU, Australia, New Zealand) plus an “other / international” fallback.

Privacy screening.

• Detects names, ages, dates, locations, employers, treatment-facility identifiers, and combined re-identification context in source transcripts.
• Three-level re-identification risk classification (low / medium / high) with a high-risk hard gate before output is revealed.

Drug and treatment-claim screening.

• Flags unapproved indications, off-label promotion language, and superlative efficacy claims.
• Surfaces flagged statistics, drug names, study citations, dates, and quantified health outcomes for the creator to verify before publishing.

Scope-of-practice screening.

• Detects personalized treatment recommendations, diagnostic claims, and dosing instructions to the general public.
• Inserts jurisdiction-appropriate disclaimer text on every output.

Ad-disclosure screening.

• Auto-adds disclosure when the creator marks content as sponsored.
• Per-jurisdiction phrasing (FTC §255, ASA, ACCC, ASAI, Competition Bureau, EU UCPD).

Regulator citations.

• Every output carries a “regulator citations applied” panel listing which bodies’ rules were screened against, so the creator can keep an audit trail.

Next scheduled review:2026-08-27 (biweekly review — monitor covered regulators for changes since v1.2.2).

Calendared screening change: v1.3.0 effective 2026-12-26 (US COVID-19 EUA device-status flip; see Update 2 above). Target ship cycle: biweekly review of 2026-12-24.

Questions about the rules database or a specific regulator update? support@snapgrove.ai.